This clinical trial is focused on studying a condition known as Chronic Inducible Urticaria, which is a type of skin condition that causes itchy welts or hives. The study is testing a treatment called Barzolvolimab, also known by its code name CDX-0159. This treatment is being compared to a placebo to see how effective it is in helping patients with this condition. The trial aims to find out if different doses of Barzolvolimab can help reduce the symptoms of Chronic Inducible Urticaria, specifically in subtypes like Cold Urticaria and Symptomatic Dermographism.

The study is designed to be a randomized, double-blind, placebo-controlled trial. This means that participants will be randomly assigned to receive either the treatment or a placebo, and neither the participants nor the researchers will know who is receiving which until the study is completed. The trial will last for several weeks, during which participants will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The main goal is to see if the treatment can help patients achieve a negative provocation test, which means they do not develop hives when exposed to certain triggers.

Throughout the study, participants will be monitored to assess the safety and effectiveness of Barzolvolimab. The trial will measure how well the treatment works by looking at changes in the symptoms of Chronic Inducible Urticaria over time. The study will also track any side effects that participants may experience. The results will help determine if Barzolvolimab is a safe and effective treatment option for people with this condition.